Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Graft Polymer (UK) PLC ( (GB:SVNS) ) has shared an announcement.
Solvonis Therapeutics plc has announced a £1.0 million investment from its major shareholders to accelerate its AI-supported drug discovery program, focusing on major depressive disorder and stimulant use disorder. This funding will enhance the company’s ability to identify and validate early-stage candidates, positioning Solvonis to address significant unmet needs in the global antidepressant and stimulant use disorder markets, which are projected to grow substantially in the coming years.
More about Graft Polymer (UK) PLC
Solvonis Therapeutics plc is a clinical-stage biopharmaceutical company focused on developing novel medicines for addiction and mental health disorders. Headquartered in London and listed on the main market of the London Stock Exchange, the company is advancing a pipeline of repurposed and novel compounds targeting high-burden neuropsychiatric conditions with significant unmet needs. Solvonis’ lead programs include treatments for Alcohol Use Disorder and Post-Traumatic Stress Disorder, with a strategic focus on comorbid and underserved neuropsychiatric conditions.
Average Trading Volume: 73,125,932
Technical Sentiment Signal: Hold
Current Market Cap: £15.95M
See more insights into SVNS stock on TipRanks’ Stock Analysis page.